Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

Clinical trial NCT06496308 · RECRUITING

Trial details

NCT number: NCT06496308
Sponsor: Ruijin Hospital
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Mantle Cell Lymphoma (MCL)

Start date: 2024-07-10
Primary completion: 2027-07-10
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.